Background. Acute kidney injury (AKI) remains associated with high morbidity and mortality, despite progress in medical care. Although the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease) and AKIN (Acute Kidney Injury Network) criteria, based on serum creatinine and urine output, were a step forward in diagnosing AKI, a reliable tool to differentiate between true parenchymal and pre-renal azotaemia in clinical practice is still lacking. In the last decade, many papers on the use of new urinary and serum biomarkers for the diagnosis and prognostication of AKI have been published. Thus, the question arises which biomarker is a reliable differential diagnostic tool under which circumstances. Methods. We searched Medline from inception to April 2012 using medical subject heading and text words for AKI and biomarkers [neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), Cystatin C, interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18 (IL-18), N-acetyl-glucosaminidase (NAG), glutathione transferases (GST) and liver fatty acid binding protein (LFABP)] to identify relevant papers in five different settings (paediatrics, cardiac surgery, emergency department, critically ill and contrast-induced nephropathy). Results. We included 87 relevant papers, reporting on 74 studies. Depending upon the setting, 7-27 different definitions of AKI were used. Reported diagnostic performance of the different biomarkers was variable from poor to excellent, and no consistent generalizable conclusions can be drawn on their diagnostic value. Conclusions. Early diagnosing of AKI in clinical conditions by using new serum and urinary biomarkers remains cumbersome, especially in those settings where timing and aetiology of AKI are not well defined. Putting too much emphasis on markers that have not convincingly proven reliability might lead to incorrect interpretation of clinical trials. Further research in this field is warranted before biomarkers can be introduced in clinical practice.
Introduction
Acute kidney injury (AKI) remains associated with high morbidity and mortality, despite progress in medical care [1] [2] [3] . In the last decade, many papers on the use of new urinary and serum biomarkers for AKI were published, mostly concluding that these biomarkers will lead to a new era with earlier diagnosis, better prognostication of outcome in terms of need for renal replacement and/or mortality, and finally better survival [4] . Nevertheless, there remains a gap between the fascinating findings at the basic science level and the clinical application of this knowledge. Objective evaluation of the available literature shows a rather disappointing picture [5] . Before we throw out the baby with the bathwater, we should evaluate what we reasonably can expect from biomarkers, what they provide today and why their performance is currently suboptimal.
Materials and methods
To identify relevant studies, we searched MEDLINE (through OvidSP) from inception to April 2012, using medical subject headings and text words for AKI and biomarkers. The full search strategy is outlined in item S1, provided as Supplementary data. To locate studies not indexed in Medline, we checked by hand the bibliography of relevant publications. We included both cohort and case-control studies evaluating the potential of biomarkers to detect AKI early or to predict the need for renal replacement therapy (RRT) in both adults and children. We excluded studies published as abstracts only and restricted to those published in English. Papers were excluded as 'invalid intervention' when they did not analyse AKI, or where not performed in humans, and as 'inappropriate design' when they did not investigate the differential diagnosis AKI versus non-AKI. Mostly, the latter studies just reported means/medians in subgroups rather than discriminatory values on the individual patient level, or insufficient data were present to calculate these. We allowed for any definition of AKI. Biomarkers included in the search strategy were neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18 (IL-18), Cystatin C, N-acetyl-glucosaminidase (NAG), liver fatty acid binding protein (LFABP) and the glutathione transferases (GST), measured either in plasma, serum or urine.
Two authors (J.V. and W.V.B.) independently screened all titles and abstracts and assessed all selected full papers for eligibility. Any disagreements were resolved by face-to-face discussion. Using a structured data extraction template, we collected details on biomarker(s) studied, outcome, AKI definition, number of patients/events and diagnostic test characteristics. Results are reported in Tables 2-6 . When not available, positive predictive value (PPV) and negative predictive value (NPV) were calculated if enough information was provided and if the study design allowed this.
Because of the heterogeneity of studies in different clinical settings, a meta-analysis or pooling of the data was deemed to be methodologically inappropriate.
Results
One thousand five hundred and thirty-two potentially relevant papers were identified by the search strategy. Based on the title and abstract, 149 papers were selected for full paper review. After checking the bibliography of relevant papers, six additional publications were selected for full Urinary and serum biomarkers for diagnosis of AKIpaper review. Eighty-seven papers reporting on 74 studies were included in the review. Sixty-eight papers were excluded for reasons outlined in Figure 1 . All biomarkers and their abbreviations as used further in the text are summarized in Table 1 .
Results of the data extraction of the 87 selected papers are presented in Tables 2-6 . We organized papers according to the five different clinical settings [ paediatrics, cardiac surgery, emergency department, critically ill patients at intensive care unit (ICU) and contrast-induced nephropathy (CIN)].
In the paediatric setting, 16 papers reporting on 11 studies were discussed. Eleven papers reporting on seven studies were conducted post-cardiac surgery [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , one studied CIN [17] , one was conducted in the emergency department setting [18] and three papers reporting on two Table 2 . Not defined in Table 2 : ARF, acute renal failure; ARD, acute renal dysfunction; Progr AKI, progressive AKI; ICU, intensive care unit; imm, immediately; ICU arr, ICU arrival; 24 h post, 24 h postoperatively; imm/3 h, immediately/3 h after surgery; POD, postoperative day; AKIN, acute kidney injury network; RIFLE crea, staging according to RIFLE based on the creatinine criterion (omitting the diuresis criterion); AKIN crea, staging according to AKIN based on the creatinine criterion (omitting the diuresis criterion); RIFLE/AKIN both, staging according to RIFLE or AKIN based on both criteria (creatinine and diuresis); CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; αGST, α-glutathione-S-transferase; πGST, π-glutathione-S-transferase; α 1 MG, α 1 microglobulin; AXT, aortic cross-clamp time; βNAG, N-acetyl-β-D-glucosaminidase; CysC, cystatine C; CCF, Cleveland Clinic Foundation Score; CPB time, CPB perfusion time; IgG, immunoglobulin G; HGF, hepatocyte growth factor; 11k-TXB 2 , 11-keto-thromboxane B 2 ; FENA, fractional excretion of sodium; FEUrea, fractional excretion of urea.
studies were conducted in critically ill children. Only one study in the paediatric setting [6] explored the use of biomarkers for early prediction of need for RRT [196 patients, 4 events, area under the receiver operating characteristic curve (AURoC) 0.86, PPV and NPV not available]. All other studies considered the predictive value for AKI, which was defined according to seven different definitions. The number of patients varied from 23 to 374, and the number of events varied from 6 to121. AURoCs for the prediction of AKI varied from 0.44 to 1.00. PPVs and NPVs ranged from 27 to 100% and from 10 to 100%, respectively. In adult cardiac surgery, 26 papers reporting on 22 studies were included. Twenty-seven different definitions for AKI were used. Patient number varied from 30 to 1219 and event number varied from 1 to 85. The AURoCs varied from 0.27 to 0.98. PPVs and NPVs ranged from 4 to 100% and from 61 to 100%, respectively. One study [19] reported on the use of biomarkers for the prediction of need for RRT (100 patients, 4 events, AURoC 0.83, PPV 100%, NPV 99%), although another study [20] also defined AKI as a 25% increase in serum creatinine (Screa) or RRT need with AURoCs between 0.54 and 0.73 and PPV 64-72%, NPV 67-73%.
In the emergency department setting, four studies were included [21] [22] [23] [24] 
Discussion
This paper evaluated the state of the art on the diagnostic usefulness of biomarkers in AKI. Most striking was the wide array of definitions used for AKI. With regard to the diagnostic usefulness of biomarkers, a variety of results Tables 2 and 3 . Not defined in Tables 2 and 3 : α 1 acidGP, α 1 acid glycoprotein; T0, at admission.
Urinary and serum biomarkers for diagnosis of AKI 261 Same as in Tables 2-4 . Not defined in Tables 2-4 : ATN, acute tubular Necrosis; AKI sust, sustained AKI; M, mortality; Rday-2/-1, 1 and 2 days before AKI diagnosed by serum creatinine; IDay-2/-1, 1 and 2 days before AKI diagnosed by serum creatinine; FDay-2/-1, 1 and 2 days before AKI diagnosed by serum creatinine; at adm, at admission; after adm, after admission; γGT, γ-glutamyl transferase; AP, alkaline phosphatase; LDH, lactate dehydrogenase; RBP, retinol-binding protein; PAI-1, plasminogen activator inhibitor-1; sTNFR-I and II, soluble tumour necrosis factor receptor I and II; IADM-1, intracellular adhesion molecule 1; TNFα, tumour necrosis factor alpha; vWF, von Willebrand factor; IL-10, interleukin-10; MP ICU-T, marker pattern ICU training set; MP ICU-V, marker pattern ICU validation set; pNGAL, plasma NGAL; PCX, podocalyxin; BL, baseline serum creatinine.
ranging from overtly negative to very optimistic were found.
There are different explanations for this wide range of results. First, widely different clinical settings are investigated, from paediatric post-cardiac bypass, where timing and amount of renal impact are exactly known, to patients with septic shock, where timing of renal insult is unknown. Overall, diagnostic performance of biomarkers appears to be better in situations with a known timing and aetiology of renal injury. Second, most of these markers are not only associated with kidney damage, but also with the underlying conditions causing AKI, such as sepsis, diabetic nephropathy, systemic lupus erythematosus and haemolytic uraemic syndrome [25] [26] [27] [28] . Some of these markers are also increased in chronic kidney disease (CKD) [29, 30] , blurring the differential diagnosis between CKD and AKI. The reference baseline creatinine of a given patient is not always available, so in these patients, it is unclear whether an increased creatinine is due to AKI or CKD. The behaviour of most biomarkers in patients with CKD is, however, largely unknown. The usefulness of biomarkers should thus be addressed differently for different clinical settings, as it is apparent that performance is strongly dependent on the underlying circumstances. As such, results in one setting cannot be generalized.
Third, one should be cautious for some statistical pitfalls when translating studies to clinical practice. Most studies report higher values for the biomarker in patients with AKI, but with a substantial overlap between AKI and non-AKI patients, hampering discrimination in the single case. AURoCs are mostly used to circumvent this problem; however, the use of this instrument is troublesome in conditions with rather low prevalence, so PPV and NPV should also be provided, to allow a good judgement on the accuracy of the biomarker. The use of odds ratios should be avoided in cases with low prevalence. In a study on performance of uNGAL for example, an impressive 16.4 higher odds ratio to need RRT was reported; however, still only 2.5% of the patients in this NGAL +/Screa− group end up on RRT, and consequently, just as for Screa, NGAL levels should thus not be used to decide on the start of RRT [31] [32] [33] .
Fourth, many studies use circular reasoning to define AKI by new markers. They start from the premise that an increase in the biomarker without a rise in Screa indicates AKI [34, 35] , thus increasing sensitivity, but at the expense of specificity and PPV. This confusion is due to the lack of a gold standard to diagnose AKI, and the difficulty to make a distinction between intrinsic renal damage (histological AKI) and physiological decrease in renal perfusion (functional AKI) in the clinical setting. Undoubtedly, there is also a grey zone, where functional and histological AKI co-exist in a varying mix. Recent work by Nejat et al. [36] indicated that even in cases of transient AKI, markers of tubular damage can be present, demonstrating that 'functional' and 'intrinsic' AKI are probably gradations of an evolving spectrum of AKI. Urinary markers will probably be more sensitive for true histological damage, whereas serum levels of markers are probably more sensitive for changes in clearance. In research conditions, e.g. to evaluate potential nephrotoxicity, the use of high-sensitivity markers is excellent. However, in clinical practice, we need to define what degree of subclinical damage as detected by biomarkers we will accept. Therefore, we need studies linking acute tubular damage to long-term outcomes. Several studies make the link between AKI, even when apparently fully recovered, and progressive CKD, but in all these, the classic definition of AKI, based on creatinine, was used, and to our knowledge, these data are lacking for biomarkers [37, 38] .
Lastly, some studies advertise the use of biomarkers in situations where the outcome already seems predictable using standard parameters, such as clinical appraisal and oliguria.
In the study of Koyner et al. [20] , seven patients needed RRT, five of them within 27 h after cardiac surgery, making it plausible that RRT need in these patients could have been predicted by bedside clinical appraisal. Also, the value of biomarkers to predict the need for RRT should be evaluated compared with other available standards, such as clinical appreciation, time on cardiopulmonary bypass (CPB) or urinary output [39] . Singer et al. [40] used uNGAL to separate intrinsic from pre-renal AKI, but 32 out of 104 patients were esteemed 'unclassifiable', and were thus not incorporated in the evaluation of the diagnostic accuracy of uNGAL. This means that only patients in whom the distinction between pre-renal azotaemia and AKI could already be established based on clinical grounds were included. From the provided graphs, it is clear that the biomarker in these 'unclassifiable' cases were also 'intermediate', and thus not discriminative. Not taking into account all these reflections can lead to erroneous conclusions on the value of biomarkers, resulting in incorrect diagnoses, and thus incorrect therapeutic interventions.
It is clear from our survey that whereas the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease) and AKIN (Acute Kidney Injury Network) classification form a giant leap forward, the definition of AKI is still problematic and that both RIFLE and AKIN are applied differently in every individual study in clinical practice, resulting in differences in classification.
The studies of Mishra et al. [12] and Bennett et al. [6] showed excellent performance for NGAL under ideal circumstances: children without co-morbidities after CPB. When more heterogenic populations were studied such as critically ill patients, results became more ambiguous [41] [42] [43] . Septic paediatric patients have higher uNGAL and IL-18 levels than non-septic patients, indicating that the association between uNGAL and AKI in septic patients might reflect more the association between the severity of disease and AKI rather than true renal damage.
Reported results on biomarkers in cardiac surgery are disappointing and conflicting, with AURoCs for uNGAL comparable to the predictive power of clinical parameters such as the duration of CPB and aortic cross-clamp time [44] [45] [46] . KIM-1 has been reported to have the best AURoC for the prediction of AKI. However, the low PPV showed that three out of four patients are being mislabelled as having AKI [47] . Plasma NGAL and IL-18 also performed poorly [48, 49] . Serum cystatin C performed reasonably when AKI was defined as an increase in Screa of 50%, but poorly when based on RIFLE. More importantly, also Screa distinguished accurately between the AKI and the non-AKI groups within 24 h after arrival at the ICU [50] . In subjects with a baseline estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m 2 , uNGAL was not able to predict the development of evolving AKI [51] . The discriminatory ability of uNGAL was less with the decreasing RIFLE class [19] . The major challenge in the emergency setting is to distinguish fluid responsiveness from non-fluid responsive AKI, and AKI from CKD. As we do not have an established clinical definition of 'pre-renal' AKI, discrimination of this condition always remains somewhat subjective.
In a study with 635 patients, 411 had normal kidney function, 80 had pre-renal azotaemia, 30 AKI and 106 non-progressive CKD [21] . This implicates that a patient with increased Screa at the emergency department has a 6-fold higher odds to have either CKD or pre-renal kidney dysfunction than to have AKI. Despite the significant difference in median uNGAL levels between the different groups, there was a substantial overlap. Most of the patients with AKI had already very high Screa levels at presentation (mean 5.6 mg/dL, standard deviation 5.5 mg/dL). In patients presenting at the emergency department with suspected sepsis, median NGAL levels were higher in patients with versus without AKI, but with substantial overlap, making discrimination per individual patient impossible [23] . In addition, patients who died without AKI had pNGAL levels comparable to the range of the AKI group, again indicating that the discriminative power of pNGAL for AKI is more related to the fact that it is a marker of the severity of disease than of kidney injury.
In a prospective cohort study of 616 patients admitted to a tertiary care emergency department, both sCysC and Screa but not uCysC differentiated between AKI and non-AKI. The authors state that sCysC distinguishes between AKI and pre-renal azotaemia. Neither biomarker discriminated between AKI and CKD [24] .
The application of biomarkers is most cumbersome in critically ill patients. As in this setting the timing of the renal insult is unknown, multiple samples will have to be taken, which all have the potential of being false-positive and may lead to logistical problems as well as being less cost-effective. The pathophysiology of AKI in sepsis patients is complex and not merely due to ischaemia/reperfusion injury, but also to inflammatory processes [52] . It is likely that the levels of many biomarkers, e.g. IL-18 or NGAL, will be influenced by these processes, irrespective of AKI [32] . Plasma markers are thus in these patients more an indication of severity of disease than of true kidney damage [33, [53] [54] [55] . Finding a biomarker or a panel of biomarkers that takes into account these different underlying pathological processes while still discriminating AKI is challenging. In most studies, there was no attempt to evaluate the discriminative power of the biomarker on top of other parameters, such as severity of sepsis, or urinary output. Although in a large cohort, uNGAL remained an independent predictor for AKI in a multivariate logistic regression model, the addition of uNGAL did not significantly improve discriminative power of the model. Overall, the clinical model performed better than uNGAL 56. In this study [56] , uNGAL had a better discriminative value than eGFR (0.79 versus 0.67) at admission in the subgroup with eGFR >60 mL/min at admission; however, no multivariate analysis on the additional discriminative value of NGAL on top of other clinical parameters was provided for this subgroup.
In ICU patients, uNGAL and pNGAL did perform worse than admission eGFR, and adding pNGAL and uNGAL to a multivariate model with eGFR only improved reclassification for AKI insignificantly [57] . Adding sCysC to a clinical model did not improve the diagnostic performance of the clinical model [58] . Urinary CysC predicted AKI, with a model including uCysC, uCrea, age, hypotension and APACHE II subcategory scores, in 444 critically ill patients, but when excluding patients with overt AKI on admission based on clinical grounds and Screa, the AURoC was only 0.54 [59] . The predictive performance of urinary IL-18 in critically ill patients was poor [60] , and uLFABP did not perform well to diagnose established AKI [61] .
Some authors showed a better diagnostic performance of biomarkers when stratifying patients according to the presence of pre-existing CKD [60, 62] .
Another strategy to optimize the performance of biomarkers in ICU patients was to use a marker pattern (20 urinary peptides) rather than individual biomarkers [63] . However, a panel of 20 peptides measured by capillary electrophoresis-mass spectrometry, with high cost and long turn-around time, might not be realistic in clinical conditions.
Also in CIN, the use of biomarkers is prone to problems. The risk for CIN increases in patients with comorbid conditions, such as diabetes or older age, and in patients with pre-existing kidney disease, all of which influence on themselves biomarker levels. In patients without pre-existing CKD, the incidence of CIN is very low. In children, plasma and serum uNGAL were reported to be better predictors for CIN than Screa [17] . The diagnosis of AKI was made using NGAL and IL-18 in adults undergoing elective coronarography, percutanous transluminal coronary angioplasty or angioplasty, up to 24 h before diagnosis by Screa, but this was not confirmed in another study [64, 65] .
Interestingly, NGAL is known to be increased in atherosclerotic plaques and might be released from these plaques during PCI without being related to kidney injury [66] . It can also be questioned whether CIN in patients with arteriography versus simple intravenous contrast administration is the same condition, as the former can also be induced by cholesterol embolism.
Conclusion
Whereas biomarkers can increase our understanding of the pathophysiology of AKI, it appears that the promising results with new biomarkers for early detection and differential diagnosis of AKI in clinical practice can only be confirmed in the setting of children without co-morbidities and with a well-defined timing of renal injury. Results are far less robust when we search for validation in adult heterogenic populations, including patients with co-morbid conditions such as diabetes mellitus, vascular disease and CKD. Whereas AURoC values sometimes look impressive, applying levels of urinary or serum biomarkers for discrimination in individual patients is hampered by wide overlap between groups, which might result in many false positives. Biomarkers reflect a general degree of severity of disease, rather than being specific for kidney injury. Before biomarkers can be advocated to diagnose AKI, further research on the implications of 'subclinical' AKI, i. e. diagnosed by the biomarker but not by an increase in creatinine or decrease of diuresis, should be performed
